Quantcast

Latest Non-alcoholic fatty liver disease Stories

2014-07-08 12:28:47

TEL AVIV, Israel, July 8, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed") today announced the recent publication of the results of its Phase IIa clinical trial of aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal. The trial manuscript, entitled "The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients with Nonalcoholic Fatty Liver Disease," provides the full report of the Phase IIa trial, which was...

2014-07-01 16:29:45

NY Times Article Brings Attention to Dangerous Lifestyle Related Epidemic and Suggests Critical Need for Therapy DENVER, July 1, 2014 /PRNewswire/ -- A recent New York Times article ("Threat Grows from Liver Illness Tied to Obesity", June 13 2014) alerting millions to the growing prevalence and seriousness of fatty liver disease revealed a stark and very concerning reality about therapeutic options. There are currently no drugs approved for either NAFLD (nonalcoholic fatty liver...

2014-06-23 09:37:29

Monash University An international team of scientists led by Monash University researchers has shown how free radicals contribute to type 2 diabetes, obesity and fatty liver disease. Type 2 diabetes and non-alcoholic fatty liver disease are key complications of obesity as 80 per cent of patients with type 2 diabetes are obese, and 75 per cent of patients who are obese or have type 2 diabetes also have fatty liver disease. The team, led by Professor Tony Tiganis from the Department...

2014-06-23 08:28:45

Company Presents Positive Preclinical Efficacy Results at ICE/ENDO 2014 Meeting RALEIGH, N.C., June 23, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin),...

2014-06-04 15:37:59

Washington University in St. Louis Studying mice, researchers have found a way to prevent nonalcoholic fatty liver disease, the most common cause of chronic liver disease worldwide. Blocking a path that delivers dietary fructose to the liver prevented mice from developing the condition, according to investigators at Washington University School of Medicine in St. Louis. The study appears in a recent issue of The Journal of Biological Chemistry. In people, nonalcoholic fatty liver...

2014-05-12 20:23:17

Dr. Michael Feiz has helped countless patients overcome such issues as obesity-related fatty liver disease LOS ANGELES, May 12, 2014 /PRNewswire/ -- People with fatty liver problems who may be considering a gastric sleeve or lap band in Beverly Hills with Dr. Michael Feiz have some new information to consider. A study of the effect of bariatric procedures on NAFLD (non-alcoholic fatty liver disease) has proven to be another weight loss surgery testimonial alongside recent evidence...

2014-05-12 08:31:08

DUBLIN and SAN DIEGO, May 12, 2014 /PRNewswire/ -- - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease pipeline assets - Adds to Shire's rare diseases portfolio and leverages this expertise, and is a perfect combination with Shire's already strong Gastrointestinal (GI) presence - Adds LUM001 in Phase 2 development for four rare and devastating hepatic diseases, two...

2014-05-07 10:40:44

Researchers from The Netherlands found that snacking on high-fat and high-sugar foods was independently associated with abdominal fat and fatty liver (hepatic steatosis). According to the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, hypercaloric diet with frequent meals increases intrahepatic triglyceride content (IHTG) and fat around the waist, but increasing meal size did not. Obesity is a global health concern with the World...

2014-05-06 16:31:52

CHICAGO, May 6, 2014 /PRNewswire/ -- Research presented this week at Digestive Disease Week® (DDW) provides insight into the development and new treatments of diseases, such as nonalcoholic fatty liver disease, colorectal cancer and ulcers. Key studies presented include: -- Weight-loss surgery can reduce liver damage. Bariatric surgery, which is best known for its ability to help patients lose weight, can also result in improvement in nonalcoholic fatty liver disease...

2014-04-14 12:30:21

A UK study investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity. The research, conducted by the King's College Hospital Paediatric Liver Centre and the University of Surrey's School of Biosciences and Medicine, and funded by the Children's Liver Disease Foundation retrospectively analyzed the medical records of 120 pediatric patients with NAFLD. The...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related